Key clinical point: Vaccinating most girls against human papillomavirus infection would reduce cervical cancer incidence by nearly 90% in low- and middle-income countries by 2120, a model suggests.
Major finding: The model predicts that girls-only human papillomavirus vaccination would reduce the median age-standardized cervical cancer incidence from 19.8 cases per 100,000 women-years to 2.1 cases per 100,000 women-years by 2120 across 78 middle- and low-income countries.
Study details: A modeling study using Global Cancer Observatory incidence estimates for 78 countries in 2018.
Disclosures: The study was funded by the World Health Organization, the United Nations, and the Canadian and Australian governments. Two study authors disclosed indirect industry funding for a cervical screening trial.
Brisson M et al. Lancet. 2020 Jan 30. doi: 10.1016/S0140-6736(20)30068-4.